-
A Prospective Randomized Open-label Phase 4 Study of the Immunology and Safety of Maternal RSV Vaccination (ABRYSVOTM) Infant Nirsevimab (BEYFORTUSTM) Immunization or Both Products During the First Year of Life
At the NYU Langone Vaccine Center, we are conducting an NIH sponsored clinical trial on two FDA-approved products that protect against RSV (Respiratory Syncytial Virus ...Phase
Interventional
